PURPOSE: In this cohort study, the rates of pulmonary embolism (PE), myocardial infarction (MI), and ischemic stroke (IS) before and after lung cancer (LC) diagnosis were compared to cancer-free controls. METHODS: Patients with LC during 2000-2007 were selected from PALGA, the Dutch Pathology Registry, and linked to the PHARMO medical record linkage system, including drug use and hospitalizations of 3 million inhabitants in the Netherlands. Included LC patients were matched 1:10 by age and gender to cancer-free controls. Hospitalizations for PE, MI, and IS were assessed in the 12 months before and after LC diagnosis. RESULTS: LC patients (N = 3,717) were six times more likely than cancer-free controls to have had a PE in the 12 months before diagnosis. After LC diagnosis, patients experienced an extremely increased risk of PE in the first 6 months (hazard ratio [HR] 16.8; 95 % confidence interval [CI] 7.6-36.8) compared with controls), which decreased to a five times increased risk (HR 5.1; 95 % CI 2.7-9.4) thereafter. However, there were less than two events per 100 person years during both time periods. LC patients receiving chemotherapy were eight times more likely to develop PE, whereas surgery increased the risk on PE three times. For MI and IS, no significant difference was observed compared with cancer-free controls before or after LC diagnosis. CONCLUSIONS: LC patients have a higher risk of developing PE compared with cancer-free controls, although the frequency of PE hospitalizations was low. Surgery and chemotherapy were associated with an increased risk of PE.
PURPOSE: In this cohort study, the rates of pulmonary embolism (PE), myocardial infarction (MI), and ischemic stroke (IS) before and after lung cancer (LC) diagnosis were compared to cancer-free controls. METHODS:Patients with LC during 2000-2007 were selected from PALGA, the Dutch Pathology Registry, and linked to the PHARMO medical record linkage system, including drug use and hospitalizations of 3 million inhabitants in the Netherlands. Included LC patients were matched 1:10 by age and gender to cancer-free controls. Hospitalizations for PE, MI, and IS were assessed in the 12 months before and after LC diagnosis. RESULTS: LC patients (N = 3,717) were six times more likely than cancer-free controls to have had a PE in the 12 months before diagnosis. After LC diagnosis, patients experienced an extremely increased risk of PE in the first 6 months (hazard ratio [HR] 16.8; 95 % confidence interval [CI] 7.6-36.8) compared with controls), which decreased to a five times increased risk (HR 5.1; 95 % CI 2.7-9.4) thereafter. However, there were less than two events per 100 person years during both time periods. LC patients receiving chemotherapy were eight times more likely to develop PE, whereas surgery increased the risk on PE three times. For MI and IS, no significant difference was observed compared with cancer-free controls before or after LC diagnosis. CONCLUSIONS: LC patients have a higher risk of developing PE compared with cancer-free controls, although the frequency of PE hospitalizations was low. Surgery and chemotherapy were associated with an increased risk of PE.
Authors: Paul D Stein; Afzal Beemath; Frederick A Meyers; Elias Skaf; Julia Sanchez; Ronald E Olson Journal: Am J Med Date: 2006-01 Impact factor: 4.965
Authors: Richard H White; Helen K Chew; Hong Zhou; Arti Parikh-Patel; David Harris; Danielle Harvey; Theodore Wun Journal: Arch Intern Med Date: 2005 Aug 8-22
Authors: Elsje R Koomen; Arjen Joosse; Ron M C Herings; Mariël K Casparie; Henk Jan Guchelaar; Tamar Nijsten Journal: Melanoma Res Date: 2009-10 Impact factor: 3.599
Authors: Vicky Tagalakis; Dahlia Levi; Jason S Agulnik; Victor Cohen; Goulnar Kasymjanova; David Small Journal: J Thorac Oncol Date: 2007-08 Impact factor: 15.609
Authors: Christianne L Roumie; Edward Mitchel; Patricia S Gideon; Cristina Varas-Lorenzo; Jordi Castellsague; Marie R Griffin Journal: Pharmacoepidemiol Drug Saf Date: 2008-01 Impact factor: 2.890
Authors: Kevin G Phillips; Angela M Lee; Garth W Tormoen; Rachel A Rigg; Anand Kolatkar; Madelyn Luttgen; Kelly Bethel; Lyudmila Bazhenova; Peter Kuhn; Paul Newton; Owen J T McCarty Journal: Am J Physiol Cell Physiol Date: 2014-11-19 Impact factor: 4.249
Authors: Clara Faubry; Maxime Faure; Anne-Claire Toublanc; Rémi Veillon; Anne-Iris Lemaître; Charlotte Vergnenègre; Hubert Cochet; Sadia Khan; Chantal Raherison; Pierre Dos Santos; Maeva Zysman Journal: Front Cardiovasc Med Date: 2022-06-06